{"id":"https://openalex.org/W7219971278","doi":null,"title":"CRYSTAL ENGINEERING OF MULTICOMPONENT SOLID FORMS OF ANTICANCER DRUGS: CO-CRYSTALS, PHARMACEUTICAL SALTS, SOLVATES, AND THEIR PHYSICOCHEMICAL OPTIMIZATION","display_name":"CRYSTAL ENGINEERING OF MULTICOMPONENT SOLID FORMS OF ANTICANCER DRUGS: CO-CRYSTALS, PHARMACEUTICAL SALTS, SOLVATES, AND THEIR PHYSICOCHEMICAL OPTIMIZATION","publication_year":2026,"publication_date":"2026-04-23","ids":{"openalex":"https://openalex.org/W7219971278"},"language":"en","primary_location":{"id":"pmh:oai:ojs2.phoenixpublication.net:article/11309","doi":null,"is_oa":true,"landing_page_url":"https://phoenixpublication.net/index.php/TTVAL/article/view/11309","pdf_url":"https://phoenixpublication.net/index.php/TTVAL/article/download/11309/11167","source":{"id":"https://openalex.org/S7407075217","display_name":"YANGI O\u2018ZBEKISTON, YANGI TADQIQOTLAR JURNALI","issn_l":"3030-3494","issn":["3030-3494"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"3030-3494","raw_type":"info:eu-repo/semantics/article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://phoenixpublication.net/index.php/TTVAL/article/download/11309/11167","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101885068","display_name":"Shakir Ali","orcid":"https://orcid.org/0000-0002-5772-3117","observed_orcids":["https://orcid.org/0000-0002-5772-3117"]},"institutions":[{"id":"https://openalex.org/I4405287382","display_name":"Fergana Medical Institute of Public Health","ror":"https://ror.org/050ycf013","country_code":"UZ","type":"education","lineage":["https://openalex.org/I4405287382"]}],"countries":["UZ"],"is_corresponding":true,"raw_author_name":"Shakir Ali","raw_affiliation_strings":["Assistant Professor Department of Medical and Biological Chemistry Fergana Medical Institute of Public Health"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Assistant Professor Department of Medical and Biological Chemistry Fergana Medical Institute of Public Health","institution_ids":["https://openalex.org/I4405287382"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5101885068"],"corresponding_institution_ids":["https://openalex.org/I4405287382"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10798","display_name":"Crystallography and molecular interactions","score":0.6875,"subfield":{"id":"https://openalex.org/subfields/1606","display_name":"Physical and Theoretical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10798","display_name":"Crystallography and molecular interactions","score":0.6875,"subfield":{"id":"https://openalex.org/subfields/1606","display_name":"Physical and Theoretical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11881","display_name":"Crystallization and Solubility Studies","score":0.29490000009536743,"subfield":{"id":"https://openalex.org/subfields/2505","display_name":"Materials Chemistry"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.0066999997943639755,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crystal-engineering","display_name":"crystal engineering","score":0.843999981880188},{"id":"https://openalex.org/keywords/cocrystals","display_name":"cocrystals","score":0.8809999823570251},{"id":"https://openalex.org/keywords/pharmaceutical-salts","display_name":"pharmaceutical salts","score":0.9850000143051147},{"id":"https://openalex.org/keywords/solvates","display_name":"solvates","score":0.9950000047683716},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.9959999918937683},{"id":"https://openalex.org/keywords/water-solubility-enhancement","display_name":"aqueous solubility enhancement","score":0.765999972820282},{"id":"https://openalex.org/keywords/hydrogen-bonding","display_name":"hydrogen bonding","score":0.6200000047683716},{"id":"https://openalex.org/keywords/crystal-packing","display_name":"crystal packing","score":0.6150000095367432},{"id":"https://openalex.org/keywords/hirshfeld-surface-analysis","display_name":"Hirshfeld surface analysis","score":0.7599999904632568},{"id":"https://openalex.org/keywords/crystal-structure-prediction","display_name":"crystal structure prediction","score":0.699999988079071},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.6809999942779541},{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.9279999732971191},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":0.8920000195503235},{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9359999895095825},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9100000262260437},{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":0.9419999718666077},{"id":"https://openalex.org/keywords/cabozantinib","display_name":"cabozantinib","score":0.9869999885559082},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9959999918937683}],"concepts":[{"id":"https://openalex.org/C5716244","wikidata":"https://www.wikidata.org/wiki/Q5191408","display_name":"Crystal engineering","level":4,"score":0.7156999707221985},{"id":"https://openalex.org/C40869318","wikidata":"https://www.wikidata.org/wiki/Q899050","display_name":"Synthon","level":2,"score":0.7081000208854675},{"id":"https://openalex.org/C88380143","wikidata":"https://www.wikidata.org/wiki/Q416674","display_name":"Dissolution","level":2,"score":0.5889000296592712},{"id":"https://openalex.org/C93275456","wikidata":"https://www.wikidata.org/wiki/Q756449","display_name":"Supramolecular chemistry","level":3,"score":0.5340999960899353},{"id":"https://openalex.org/C155574463","wikidata":"https://www.wikidata.org/wiki/Q170731","display_name":"Solubility","level":2,"score":0.4666000008583069},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.444599986076355},{"id":"https://openalex.org/C171250308","wikidata":"https://www.wikidata.org/wiki/Q11468","display_name":"Nanotechnology","level":1,"score":0.4415000081062317},{"id":"https://openalex.org/C115624301","wikidata":"https://www.wikidata.org/wiki/Q895901","display_name":"Crystal structure","level":2,"score":0.4311000108718872},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.4253000020980835},{"id":"https://openalex.org/C2781285689","wikidata":"https://www.wikidata.org/wiki/Q21921428","display_name":"Crystal (programming language)","level":2,"score":0.4221000075340271},{"id":"https://openalex.org/C184651966","wikidata":"https://www.wikidata.org/wiki/Q906356","display_name":"Aqueous solution","level":2,"score":0.38909998536109924},{"id":"https://openalex.org/C21951064","wikidata":"https://www.wikidata.org/wiki/Q899212","display_name":"Combinatorial chemistry","level":1,"score":0.385699987411499},{"id":"https://openalex.org/C166950319","wikidata":"https://www.wikidata.org/wiki/Q245031","display_name":"Intermolecular force","level":3,"score":0.3637000024318695},{"id":"https://openalex.org/C2781047461","wikidata":"https://www.wikidata.org/wiki/Q679692","display_name":"Biopharmaceutical","level":2,"score":0.32919999957084656},{"id":"https://openalex.org/C203036418","wikidata":"https://www.wikidata.org/wiki/Q284256","display_name":"Crystallization","level":2,"score":0.3260999917984009},{"id":"https://openalex.org/C107054158","wikidata":"https://www.wikidata.org/wiki/Q25257","display_name":"Precipitation","level":2,"score":0.3172000050544739},{"id":"https://openalex.org/C53105671","wikidata":"https://www.wikidata.org/wiki/Q14777816","display_name":"Rational design","level":2,"score":0.31529998779296875},{"id":"https://openalex.org/C26456737","wikidata":"https://www.wikidata.org/wiki/Q185154","display_name":"Crystal growth","level":2,"score":0.3019999861717224},{"id":"https://openalex.org/C2182769","wikidata":"https://www.wikidata.org/wiki/Q62500","display_name":"Ionic bonding","level":3,"score":0.2953999936580658},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.27810001373291016},{"id":"https://openalex.org/C99726746","wikidata":"https://www.wikidata.org/wiki/Q906396","display_name":"Chemical space","level":3,"score":0.2768999934196472},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.2621000111103058},{"id":"https://openalex.org/C2777212361","wikidata":"https://www.wikidata.org/wiki/Q5127848","display_name":"Class (philosophy)","level":2,"score":0.2596000134944916},{"id":"https://openalex.org/C183696295","wikidata":"https://www.wikidata.org/wiki/Q2487696","display_name":"Biochemical engineering","level":1,"score":0.2590999901294708},{"id":"https://openalex.org/C73922627","wikidata":"https://www.wikidata.org/wiki/Q754943","display_name":"Single crystal","level":2,"score":0.25029999017715454}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:ojs2.phoenixpublication.net:article/11309","doi":null,"is_oa":true,"landing_page_url":"https://phoenixpublication.net/index.php/TTVAL/article/view/11309","pdf_url":"https://phoenixpublication.net/index.php/TTVAL/article/download/11309/11167","source":{"id":"https://openalex.org/S7407075217","display_name":"YANGI O\u2018ZBEKISTON, YANGI TADQIQOTLAR JURNALI","issn_l":"3030-3494","issn":["3030-3494"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"3030-3494","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:ojs2.phoenixpublication.net:article/11309","doi":null,"is_oa":true,"landing_page_url":"https://phoenixpublication.net/index.php/TTVAL/article/view/11309","pdf_url":"https://phoenixpublication.net/index.php/TTVAL/article/download/11309/11167","source":{"id":"https://openalex.org/S7407075217","display_name":"YANGI O\u2018ZBEKISTON, YANGI TADQIQOTLAR JURNALI","issn_l":"3030-3494","issn":["3030-3494"],"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"3030-3494","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.4043000042438507}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7219971278.pdf","grobid_xml":"https://content.openalex.org/works/W7219971278.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4417067248","https://openalex.org/W3187309927","https://openalex.org/W2780345675","https://openalex.org/W2776306832","https://openalex.org/W2745791103","https://openalex.org/W7008033489","https://openalex.org/W7036857745","https://openalex.org/W4366547403","https://openalex.org/W1497571739","https://openalex.org/W7220375854"],"abstract_inverted_index":{"Anticancer":[0],"active":[1],"pharmaceutical":[2,272],"ingredients":[3],"(APIs)":[4],"comprise":[5],"a":[6,20,54,78,268],"diverse":[7],"and":[8,59,80,105,121,160,172,184,208,231,243,258,277],"expanding":[9],"catalogue":[10],"of":[11,42,48,71,84,89,221,285],"small-molecule":[12],"therapeutics":[13],"that,":[14],"despite":[15],"remarkable":[16],"pharmacological":[17],"sophistication,":[18],"share":[19],"common":[21],"physicochemical":[22,182,205],"liability:":[23],"poor":[24],"aqueous":[25],"solubility":[26],"classified":[27],"predominantly":[28],"within":[29],"BCS":[30],"Class":[31,34],"II":[32],"or":[33,186],"IV.":[35],"Crystal":[36],"engineering":[37,111],"\u2014":[38,52,93,107],"the":[39,68,72,127,218,240,282],"rational":[40],"design":[41],"crystalline":[43],"materials":[44],"through":[45],"deliberate":[46],"exploitation":[47],"non-covalent":[49],"intermolecular":[50],"interactions":[51],"provides":[53],"scientifically":[55],"rigorous,":[56],"intellectually":[57],"coherent,":[58],"regulatory-tractable":[60],"strategy":[61],"for":[62,150,215,252,271],"improving":[63],"solid-state":[64,283],"performance":[65,206],"without":[66],"altering":[67],"covalent":[69],"structure":[70,228],"drug":[73],"molecule.":[74],"This":[75,264],"review":[76,265],"delivers":[77],"systematic":[79],"critically":[81],"evaluated":[82,247],"examination":[83],"multicomponent":[85],"solid":[86],"forms":[87],"(MCSFs)":[88],"fourteen":[90],"anticancer":[91],"drugs":[92],"imatinib,":[94],"5-fluorouracil,":[95],"erlotinib,":[96],"gefitinib,":[97],"sorafenib,":[98],"lapatinib,":[99],"cabozantinib,":[100],"venetoclax,":[101],"palbociclib,":[102],"dasatinib,":[103],"tamoxifen,":[104],"nilotinib":[106],"prepared":[108],"by":[109],"crystal":[110,194,227],"approaches":[112],"spanning":[113],"solution":[114],"crystallization,":[115],"mechanochemistry,":[116],"hot-stage":[117],"methods,":[118],"spray":[119],"drying,":[120],"hot-melt":[122],"extrusion.":[123],"Structural":[124,129],"data":[125],"from":[126,239],"Cambridge":[128],"Database":[130],"(CSD)":[131],"are":[132,235,246],"analyzed":[133],"in":[134,281],"depth,":[135],"with":[136],"single-crystal":[137],"X-ray":[138],"diffraction":[139],"(SCXRD)":[140],"crystallographic":[141],"parameters":[142],"(unit":[143],"cell,":[144],"space":[145],"group,":[146],"density,":[147],"R-factors)":[148],"compiled":[149],"eight":[151],"benchmark":[152],"co-crystal":[153],"systems":[154],"(Table":[155,164],"2),":[156],"alongside":[157],"hydrogen-bond":[158,224],"geometry":[159],"Etter":[161],"graph-set":[162],"notation":[163],"3).":[165],"Five":[166],"comprehensive":[167,269],"tables":[168],"provide":[169],"CSD":[170],"refcodes":[171],"CCDC":[173],"deposit":[174],"numbers,":[175],"solubility,":[176],"intrinsic":[177],"dissolution":[178,222],"rates":[179],"(IDR),":[180],"coformer":[181,233],"criteria,":[183],"regulatory":[185,278],"stability":[187],"data.":[188],"Six":[189],"annotated":[190],"figure":[191],"panels":[192],"describe":[193],"packing":[195],"motifs,":[196],"ORTEP":[197],"diagrams,":[198],"Hirshfeld":[199],"surface":[200],"analyses,":[201],"supramolecular":[202],"synthon":[203],"hierarchies,":[204],"comparisons,":[207],"continuous":[209],"manufacturing":[210],"schematics.":[211],"The":[212],"\u0394pKa":[213],"rule":[214],"salt/co-crystal":[216],"assignment,":[217],"thermodynamic":[219],"basis":[220],"enhancement,":[223],"propensity":[225],"analysis,":[226],"prediction":[229],"(CSP),":[230],"machine-learning-based":[232],"selection":[234],"addressed.":[236],"Regulatory":[237],"frameworks":[238],"FDA":[241],"(2018)":[242,245],"EMA":[244],"against":[248],"clinical":[249],"development":[250],"evidence":[251],"gefitinib":[253],"fumarate":[254,260],"(NMPA":[255],"approval,":[256],"2019)":[257],"palbociclib":[259],"(Phase":[261],"II,":[262],"US).":[263],"serves":[266],"as":[267],"reference":[270],"scientists,":[273],"crystallographers,":[274],"formulation":[275],"chemists,":[276],"scientists":[279],"engaged":[280],"optimisation":[284],"oncology":[286],"medicines.":[287]},"counts_by_year":[],"updated_date":"2026-10-24T09:50:30.924529","created_date":"2026-10-05T00:00:00"}